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Curative resection for gastrointestinal cancer often fails because of
local tumour recurrence. This is a catastrophic event for the patient
and a substantial problem for the clinician, as it is seldom
amenable to further surgical resection. Strategies that reduce the
incidence of this complication should improve the prognosis of
these common malignancies.
The peritoneum is the host tissue for tumour cells disseminated
within the abdominal cavity, and is composed of an inner meso-
thelial cell monolayer supported on a connective tissue matrix
(diZerega and Rodgers, 1993). Surgical exploration traumatizes
this peritoneal lining, leading to the synthesis of a cytokine-rich
inflammatory exudate (Badia et al, 1996). Interleukin-1b (IL-1b),
tumour necrosis factor-a (TNF-a) and interleukin-6 (IL-6) are
present early in the inflammatory response, and stimulate the local
production of growth factors that promote peritoneal repair and
healing (Fukasawa et al, 1989). This growth factor-rich environ-
ment may provide a favourable milieu for the establishment of
secondary tumour metastases (Radinsky, 1993).
Although little is known about the growth factors produced by
the human peritoneum in response to trauma, basic fibroblast
growth factor (bFGF), heparin-binding epidermal growth factor-
like growth factor (HB-EGF) and vascular epidermal growth
factor (VEGF) are ubiquitously expressed in healing wounds.
They share a common heparin-binding ability which is critical 
to their function, enabling them to bind to heparan-sulphate
proteoglycans on cell surfaces and in the extracellular matrix.
Unlike bFGF and HB-EGF, several different isoforms of VEGF
are produced by alternate mRNA splicing (Houck et al, 1991),
which differ in their heparin-binding properties: VEGF206 and
VEGF189 show a high, VEGF165 an intermediate, and VEGF121 a
low affinity for heparin.
In addition to their role in wound healing, HB-EGF, bFGF and
VEGF are also implicated in the metastatic process. HB-EGF is a
ligand for the EGF receptor (EGFR), which is frequently up-regu-
lated in gastrointestinal tumours, and may have a role as a host-
derived paracrine growth factor (Miyoshi et al, 1997). bFGF is an
important growth factor in the gastrointestinal tract and may act as
an autocrine growth factor in oesophageal cancer (Iida et al, 1994).
VEGF acts synergistically with bFGF, augmenting tumour cell
metastasis by up-regulating endothelial adhesion molecules
(Pepper et al, 1992). In addition, the VEGF165 variant may exert a
direct effect on tumour cell behaviour by binding of its heparin-
binding domain to tumour cell receptors (Soker et al, 1996, 1998).
All three growth factors, HB-EGF, bFGF and VEGF, have angio-
genic properties.
Given their diverse attributes, it may be hypothesized that the
production of these growth factors by the surgically injured peri-
toneum may play a significant role in local tumour recurrence. The
aim of the current study was to determine whether peritoneal
mesothelial cells produce bFGF, HB-EGF and VEGF and to deter-
mine the effect of cytokine stimulation on growth factor expres-
sion. IL-1b, TNF-a and IL-6 were chosen as representative
cytokines generated in the peritoneal inflammatory response. The
T-cell-associated cytokine, IL-2, was studied for comparison, as it
was thought unlikely to produce any effect.
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Mesothelial cell culture and characterization
Samples of greater omentum were obtained from patients under-
going elective abdominal surgery (local ethical committee
approved) and subjected to enzymatic disaggregation, as described
previously (Stylianou et al, 1990). Briefly, omental samples were
cut into approximately 10-cm2 pieces, washed in phosphate-
buffered saline (PBS) and incubated in HBSS supplemented 
with 0.1% glucose (w/v), penicillin–streptomycin (50 IU ml–1, 
50 mg ml–1), and 0.25% trypsin (v/v) for 20 min at 37 C.
Following incubation, samples were centrifuged at 100 g for 5 min
and the omentum and supernatant discarded. The cell pellet was
resuspended in Ham’s F12 culture medium supplemented with
10% fetal calf serum (FCS), penicillin–streptomycin (50 IU ml–1,
50 mg ml–1), insulin (0.1 IU ml–1) and holo-transferrin (5 mg ml–1,
Sigma, Poole, UK) and seeded at 1 ¥ 105 cells ml–1 into 75-cm2
tissue culture flasks. This complete medium was used throughout,
apart form the induction of resting cultures and in stimulation
experiments when a reduced medium of Ham’s F12 supplemented
with 1% FCS was substituted. All cultures were incubated at 37 C,
5% carbon dioxide/95% oxygen, and the media changed every 3
days.
Primary cultures were characterized by indirect fluorescent
immunocytochemistry. Representative cells were grown to
confluence on 1% gelatin (w/v)-coated glass slides, washed in
PBS, and fixed with 4% paraformaldehyde (pH 7.4) for 10 min 
at 4 C. Slides were blocked with 10% rabbit serum (Dako,
Buckinghamshire, UK) and incubated for 1 h at room temperature
with mouse primary antibodies directed against human cytokeratin
8, 18, vimentin, BerEp4, von Willebrand factor (Dako) and calre-
tinin (Chemicon, Harrow, UK). Following 3 washes in PBS, slides
were incubated with a fluorescein isothiocyanate (FITC)-labelled
rabbit anti-mouse secondary antibody for 1 h at room temperature,
washed in PBS and visualized using a Leitz™ fluorescent micro-
scope.
Cytokine stimulation, RNA extraction and semi-
quantitative RT-PCR
Primary mesothelial cultures were passaged with 0.25% trypsin–
EDTA (v/v), seeded into gelatin-coated 24-well culture dishes at 
1 ¥ 105 cells well–1 and grown to confluence. Confluent cultures
were rested for 24 h in reduced medium prior to stimulation.
Reduced medium alone or supplemented with physiological doses
(0.1, 0.2, 0.5, 1.0, 2.0 ng ml–1) of IL-1b, TNF-a, IL-6, or IL-2
(R&D Systems, Oxon, UK) was used to challenge the cultures for
differing time points. To exclude extraneous sources of growth
factor stimulation, additional experiments were performed using
reduced medium supplemented with cytokine carrier protein
(0.1% bovine serum albumin (BSA), Sigma), or endotoxin
(lipopolysaccharide, 10 ng ml–1, Sigma).
Total RNA was extracted using the cationic detergent
Catrimox™ (VH Bio Ltd, Newcastle-upon-Tyne, UK) and 10-ml
reverse transcribed with oligo dT15 (0.5 mg), MMLV-RT (Promega,
Southampton, UK, 120 U), dNTPs (1 mM each), RNAsin
(Promega, 20 U), magnesium chloride (MgCl2) (2 mM) to a total
volume of 20 ml at 42 C for 55 min and inactivated at 95 C for 
5 min. cDNA was amplified in multiplex reactions using pre-
aliquoted polymerase chain reaction (PCR) master mix tubes
(Advanced Biotechnologies, Surrey, UK) containing 1 mM primer,
0.625 U  Taq DNA Polymerase, 75 mM Tris–HCl, 20 mM
(NH4)2SO4, 2 mM MgCl2, 0.01% (v/v) Tween-20 and 0.2 mM
dNTPs to a total volume of 25 ml. PCR was performed for 35
cycles of 1 min at 95 C, 1 min at 55 C, 1 min at 72 C and a final
elongation step of 5 min at 72 C. Gene-specific primers were
designed to span at least one intron and titrated against the house-
keeper gene, glyceraldehyde-3-phosphodehydrogenase (GAPDH),
for multiplex PCR. The following growth factor primer sets were
used: bFGF: forward CTGTACTGCAAAAACGGG, reverse
AAAGTATAGCTTTCTGCCA; HB-EGF: forward TTATCCTC-
CAAGCCACAAGC, reverse ACAGATGACAGCACCACAGC;
VEGF(total): forward CTACCTCCACCATGCCAAGT, reverse
ATGTTGGACTCCTCAGTGGG;  VEGF(spliced variants): forward
GCACAACAAATGTGAATGCAG, reverse TGGTGAGAGATC-
TGGTTCCC; GAPDH: forward GAGTCAACGGATTTGGTCGT,
reverse TTCCCGTTCTCAGCCTTGAC. All experiments incl-
uded control reactions excluding the template or using untran-
scribed RNA. Amplified products were separated on 2% agarose
gels and visualized by ethidium bromide ultraviolet fluorescence.
Semi-quantitative analysis was performed using a digital image
analysis system (Gelbase™, UV Products, Cambridge, UK)
Growth factor expression was recorded relative to that of GAPDH.
VEGF-spliced variants identified by primers spanning the splicing
site (exons 4 and 8) were purified using a cDNA extraction kit
(Qiagen, Surrey, UK) and sequenced by Oswel Laboratories Ltd,
Southampton, UK.
Identification of mesothelial IL-2 receptor message by
RT-PCR
Mesothelial cells were grown to confluence in 24-well culture
dishes, and rested in reduced medium for 24 h. Cultures were chal-
lenged with reduced medium alone or supplemented with cytokine
(1 ng ml–1 IL-1bor TNF). Total RNA was extracted from unstimu-
lated and cytokine activated cells after 4-h incubation, and
subjected to reverse transcription PCR (RT-PCR) as described
above. Gene-specific primers for the a-, b- and g c-chains of the 
IL-2 receptor were: a-chain: forward ATGGGAAAATGAA
GCCACAG, reverse GACGAGGCAGGAAGTCTCAC; 
b-chain: forward TCTCCCTCCAAGTTGTCCAC, reverse TCA-
GGACCTTCTTCAGCCAT;  g-chain: forward GTGCTCAG-
CATTGGAGTGAA, reverse ACTGACGAGGCAGAGTCGTT.
Mononuclear cells from normal subjects were isolated by standard
Ficol separation (Lymphoprep™, Nycomed Pharma, Birmingham,
UK), and activated by incubation with 2 mg/ml phytohaemagglu-
tinin (PHA, Sigma) in RPMI plus 10% FCS culture medium for 3
days, and used as positive controls for IL-2 receptor expression.
Western blotting of mesothelial cell lysates for HB-EGF
Mesothelial cells were grown to confluence in gelatin-coated 25-
cm2 tissue culture flasks, and rested in reduced medium for 24 h
prior to stimulation with 1 ng ml–1 of cytokine. Cells were scraped
free, washed in PBS and boiled in RIPA/Laemmli (Laemmli,
1970) buffer (1:2 v/v) containing b-mercaptoethanol (1:20, v/v)
for 5 min. Cell lysates were electrophoresed on 18% polyacryl-
amide gels, transferred to nitrocellulose membranes, blocked 
with 1% dried milk power in PBS (w/v) and stained with goat 
anti-human HB-EGF polyclonal antibody (1:200, R&D Systems)
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(1:500, Dako). After washing in PBS, membranes were incubated
with an appropriate horseradish peroxidase (HRP)-labelled
secondary antibody and visualized by enhanced chemilumines-
cence (Supersignal™, Pierce & Warriner, Chester, UK) on
Hyperfilm™ (Amersham Life Sciences, Buckinghamshire, UK)
Mesothelial cell conditioned media ELISA
Mesothelial cells were grown to confluence in gelatin-coated 25-
cm2 tissue culture flasks and rested in reduced medium for 24 h.
Cultures were stimulated with 1 ng ml–1 of cytokine in 5 ml of
reduced medium for a further 24 h. Control (unconditioned)
cytokine supplemented media were incubated in identical culture
flasks under the same conditions. Both mesothelial conditioned
and unconditioned media were centrifuged at 100 g for 5 min.
Analysis of VEGF in the supernatants was performed using
standard ELISA methodology (R&D Systems) according to the
manufacturer’s instructions.
RESULTS
Mesothelial culture and characterization
Primary mesothelial cells grew to form confluent cultures with 
a characteristic cobblestone appearance. Immunocytochemistry
detected strong intracellular staining for cytokeratin 8, 18,
vimentin and calretinin, confirming the mesothelial phenotype and
excluding fibroblast culture. Contamination by endothelial and
epithelial cells was excluded by negative staining for von
Willebrand factor and BerEp4 surface antigen respectively.
Growth factor analysis by semi-quantitative RT-PCR
Resting mesothelial cultures constitutively expressed bFGF, HB-
EGF and VEGF mRNA. The early inflammatory cytokines IL-1b
and TNF-a produced a significant dose- and time-dependent
increase in HB-EGF (Figure 1A) and total VEGF (Figure 1B)
levels compared to control unstimulated samples. This effect was
maximal at 4 h post-stimulation and after treatment with 1 ng ml–1
of cytokine (Figure 2 A, B). Neither BSA nor endotoxin affected
mesothelial growth factor expression within the time course of the
experiments, excluding these as a source of growth factor stimula-
tion. IL-6 produced only marginal up-regulation in HB-EGF and
VEGF expression within the 8-h time period of the experiments
(Figure 2C). None of these cytokines had an effect on mesothelial
bFGF expression.
The T-cell associated cytokine, IL-2, was found to have a
pronounced suppressive effect on HB-EGF and bFGF expression
(Figure 2D) but little effect on VEGF expression. Suppression was
maximal 8 h post-stimulation, and subsequently mRNA levels
returned towards resting values.
Further analysis of mesothelial VEGF expression revealed the
presence of two spliced variants. Both variants were up-regulated
in response to IL-1b and TNF-a stimulation (Figure 1C). Direct
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Figure 1 Representative electrophoretic gels showing the effect of cytokine
stimulation on mesothelial growth factor expression. (A) Up-regulation of 
HB-EGF but constant bFGF expression, (B) up-regulation of total VEGF
expression, (C) up-regulation of spliced variants VEGF121 and VEGF165.
GAPDH = housekeeper gene
Figure 2 Semi-quantitative analysis of the effect of cytokine stimulation on
resting mesothelial growth factor expression. Values are the median of at
least 6 experiments, normalized for controls (100%). (A) IL-1b, (B) TNF-a,
(C) IL-6, (D) IL-2. *P < 0.05 relative to controls, Mann–Whitney U-test. 
n n bFGF; n VEGF; HB-EGFsequencing identified these variants as the intermediate heparin
binding VEGF165 and the non-heparin binding VEGF121.
Expression of mesothelial IL-2 receptor by RT-PCR
As anticipated, PHA activated T-cells showed strong expression of
all three components (a-, b-, g c-chains) of the high affinity IL-2
receptor. By contrast, resting mesothelial cultures showed strong
expression of the b- and g c-chains with only weak expression 
of the a-chain, indicating the intermediate-affinity (b/g c) IL-2
receptor as the predominant expressed form (data not shown).
Interestingly, mesothelial activation with 1 ng ml–1 IL-1b or TNF-
a resulted in complete loss of IL-2 receptor message.
Western blotting for mesothelial HB-EGF protein
Western blotting of mesothelial cell lysates was used to confirm
cytokine-induced up-regulation at the protein level. Figure 3
shows the effect of 1 ng ml–1 IL-1b and TNF-a on mesothelial
HB-EGF protein production, compared to unstimulated cells.
Under reducing conditions, a single 22 kDa band was detected in
both resting and cytokine activated cultures. In agreement with the
mRNA results, both IL-1b and TNF-a up-regulate HB-EGF, but
this was most pronounced following IL-1b stimulation. Up-regu-
lation was detectable after 4 h of cytokine stimulation and main-
tained at 8 h.
Estimation of mesothelial VEGF production by ELISA
RT-PCR analysis had shown mesothelial VEGF expression to
consist of the intermediate and non-membrane binding isoforms,
VEGF165 and VEGF121 respectively. Standard ELISA methods
were therefore used to quantify VEGF secretion in conditioned
media. Mesothelial cells incubated in reduced medium showed
constitutive expression of VEGF protein (0.8 ng ml–1) following
24 h incubation (Figure 4). This was significantly increased
following incubation with IL-1b or TNF-a supplemented media
(1.5 ±0.1 and 1.3 ±0.1 ng ml–1 respectively). IL-6 and IL-2 had no
effect on VEGF secretion compared to control samples.
DISCUSSION
Mesothelial cells form the innermost layer of the human peri-
toneum, where they secrete a variety of surfactant-like molecules
that aid visceral motility and prevent adhesion formation
(Chailley-Heu et al, 1997). Recently, attention has focused on their
role in the peritoneal inflammatory response, both as a source of
cytokine production and as an interactive surface for cellular
defence mechanisms (Topley et al, 1996). They are responsive to
the early inflammatory cytokines and under the influence of IL-1b,
TNF-a or bacterial haptens, they secrete a variety of cytokines
(IL-1a, IL-1b, IL-6), growth factors (GM-CSF, G-CSF, M-CSF)
(Lanfrancone et al, 1992) and chemokines (IL-8, RANTES, MCP-
1) (Kinnaert et al, 1996) that are integral to peritoneal inflamma-
tion. They share similar properties with endothelial cells, and
express the adhesion molecules ICAM-1, VCAM-1 and PECAM-
1 (Klein et al, 1995) which facilitate lymphocyte trafficking into
the peritoneal cavity. However, the role of mesothelial cells and
their growth factors in peritoneal repair is less well established. In
particular, the production of heparin-binding growth factors such
as bFGF, HB-EGF and VEGF by activated human mesothelial
cells has not previously been explored.
These experiments have shown for the first time that concentra-
tions of IL-1b and TNF-a, achieved after surgical operations on
the peritoneum, stimulate the production of HB-EGF and VEGF in
resting human mesothelial cell cultures. Maximal up-regulation
occurred within 4 h of stimulation, suggesting a role for these
growth factors in the early peritoneal inflammatory response. Such
a role is conceivable for VEGF, previously known as vascular
permeability factor (VPF), but the biological role of HB-EGF in
this context is less obvious. Of interest is the similar dose and time
responses displayed by HB-EGF and VEGF when subjected to
cytokine stimulation, and it is interesting to speculate that they
may share a common mesothelial regulatory mechanism.
Somewhat surprisingly, IL-2 produced a marked suppression in
HB-EGF and bFGF expression in confluent cultures and may play
a role in maintaining mesothelial cells in the resting state, as loss
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Figure 3 (A) Western blot of mesothelial cell lysates showing effect of
cytokine stimulation on HB-EGF production. Lanes 1, 2 and 3 after 4 h
stimulation; lanes 4, 5 and 6 after 8 h. Lanes 1 and 4 = unstimulated; lanes 2
and 5 = IL-1b (1 ng ml–1); lanes 3 and 6 = TNF-a (1 ng ml–1). (B) Constant
expression of the loading control, cytokeratin 18 (cyto. 18)
Figure 4 The effect of cytokine stimulation on mesothelial VEGF
production. Rested confluent mesothelial cells were incubated for 24 h in
reduced media alone or supplemented with 1 ng ml–1 of cytokine and VEGF
production determined by ELISA. Values are the medians of 6 experiments,



























)of IL-2 receptor mRNA occurred upon activation with IL-1b or
TNF-a. The source of IL-2 in the resting peritoneum has not been
explored, but an autocrine mechanism is unlikely as IL-2 tran-
scripts have not been detected in long-term mesothelial cultures
(Lanfrancone et al, 1992). Investigation of the IL-2 receptor status
in resting mesothelial cells revealed strong expression of mRNA
for the b- and g c-chains that constitute the intermediate-affinity
(bg ) binding receptor. The g c-chain is the major signalling compo-
nent of the IL-2 receptor, but is common to other cytokine recep-
tors (IL-4, IL-7 and IL-13) (Farner et al, 1997). Indeed, IL-13 has
been shown to up-regulate mesothelial VCMA-1 (but not ICAM-
1) expression (Sironi et al, 1994), although the effect of IL-4 
and IL-7 on mesothelial function has not yet been reported.
Interestingly, IL-2 has previously been investigated as a potential
adjuvant in intraperitoneal immunotherapy and, in a murine
model, the combined injection of lymphokine activated killer
(LAK) cells and IL-2 produced a significant reduction in intraperi-
toneal tumour mass and prolonged survival (Ottow et al, 1987).
However, when tumour inoculation was preceded by laparotomy,
the therapeutic effects of IL-2 and LAK cell therapy were
completely abrogated, with excessive tumour growth at sites of
peritoneal trauma (Eggermont et al, 1988). In light of our current
findings, part of the anti-tumour effect attributed to IL-2 may be
due to its suppressive effect on resting mesothelial growth factor
production.
The role of heparin-binding growth factors, such as bFGF, HB-
EGF and VEGF, in peritoneal metastasis formation remains to be
fully elucidated. HB-EGF is a ligand for the EGFR, which is
frequently up-regulated in gastrointestinal tumours, and correlates
with tumour aggressiveness and prognosis (Radinsky et al, 1995;
Tokunaga et al, 1995). We have previously demonstrated the
importance of this growth factor receptor in pancreatic cancer
growth (Davies et al, 1993; Gillespie et al, 1993), and others have
shown a mitogenic effect of HB-EGF on human gastric (Naef et al,
1996) and pancreatic cancer cell lines (Kobrin et al, 1994). It is
envisaged that the production of HB-EGF by the human peri-
toneum may act as a host-derived growth factor for disseminated
gastrointestinal tumour cells. In addition to its proliferative effects,
HB-EGF may contribute to other aspects of the metastatic process.
It has been shown to promote tumour cell adhesion in human
oesophageal (Sato et al, 1996) and breast cancer cells (Narita et al,
1996) by stimulating cellular integrin expression. A similar mech-
anism is envisaged for the adhesion of disseminated gastroin-
testinal tumour cells to the activated peritoneum. In in vitro
models, HB-EGF promotes endothelial tubule formation in type I
collagen gels (Ushiro et al, 1996), and its production by activated
mesothelial cells may play a role in peritoneal angiogenesis.
bFGF stimulates the proliferation of several intestinal epithelial
cell lines (Dignas et al, 1994) and is an important growth factor in
the gastrointestinal tract. Human oesophageal cancer cells have
been shown to produce mRNA for bFGF and its receptor, FGFR1,
suggesting an autocrine role in oesophageal cancer (Iida et al,
1994). Although we failed to demonstrate a cytokine-induced
stimulation of mesothelial bFGF, the cellular trauma associated
with surgery is probably the main mechanism by which cytosolic
bFGF is released (D’Amore, 1990; Ku and D’Amore, 1995). In
this way, bFGF is free to stimulate fibroblast proliferation, interact
with metastatic tumour cells and induce angiogenesis (Montesano,
1992).
The role of VEGF in peritoneal tumour metastasis is not
confined to angiogenesis. In combination with bFGF, it up-
regulates the expression of the endothelial adhesion molecules,
VCAM-1 and ICAM-1 (Melder et al, 1996), and the VEGF165
variant exerts a direct effect on cell migration and morphology by
interaction of its heparin-binding domain with tumour cell recep-
tors (Soker et al, 1996).
The significance of these growth factors for counteracting peri-
toneal metastasis lies in their heparin-binding ability. This prop-
erty is essential to their biological action, enabling them to bind to
heparan-sulphate proteoglycans on the cell membrane and extra-
cellular matrix (Rapraeger, 1991, 1994). The purpose of this inter-
action is believed to be multifold; preventing molecular diffusion,
providing a potential extracellular growth factor store, and
initiating high affinity ligand–receptor interaction. The addition of
exogenous heparin disrupts this proteoglycan association, and in
the human colon cancer cell line, Caco-2, inhibits bFGF-induced
growth and migration responses (Jayson and Gallagher, 1997). In
the murine model, the concomitant administration of heparin to
mice inoculated with intra-abdominal tumour cells reduces the
formation of metastasis at sites of peritoneal trauma (Goldstein et
al, 1993).
We have demonstrated that HB-EGF, bFGF and VEGF, are
produced by human mesothelial cells and their expression is
significantly up-regulated by culture in a cytokine-rich environ-
ment. Such an environment exists within the peritoneal cavity
immediately after surgical intervention, when free cancer cells
may be spilled during the course of the resection. By selectively
targeting their common heparin-binding affinity, it should be
possible to substantially alter the growth factor environment of the
traumatized peritoneum, making it less favourable for metastatic
growth. In this way, the infusion of heparin-like solutions in the
post-operative period may provide an effective adjuvant to
reducing the incidence of local tumour recurrence.
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